Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 15, 2025

5 high-profile CEOs who were famously ousted from their companies

View original at finance.yahoo.com
5 high-profile CEOs who were famously ousted from their companies Thousands of companies are listed on America’s stock exchanges, and there are thousands more that are privately held and have the potential to go public…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 9.2 billion yen ($85 million) recorded by Nissan in Q3 2018 was tied to Ghosn's compensation scheme

    80% confidence
  • Theranos would generate about $1 billion in revenue in 2015

    80% confidence
  • Holmes and Balwani defrauded doctors and patients by making false claims concerning Theranos's ability to provide accurate, fast, reliable, and cheap blood tests and test results

    80% confidence
  • Theranos's claims of conducting a complete blood test from just a few drops of blood were exaggerated

    80% confidence
  • Uber adopted recommendations designed to improve culture, promote fairness and accountability, and establish processes to ensure past mistakes will not be repeated

    80% confidence
  • Elizabeth Holmes was the youngest self-made billionaire woman with a net worth of $4.5 billion

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
5 high-profile CEOs who were famously ousted from their companies — Source | Via News | ViaNews Market